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Abstract
Objective: The aim of this study was to evaluate the 10-year major osteoporotic and hip fracture risks in patients with a recent hip fracture. 
Material and Methods: The study population comprised 58 patients (32 male and 26 female, mean age 79.1 years) with a recent hip fracture. A 
bedside questionnaire including fracture risk assessment tool (FRAX®) variables and fall frequency was administered to the patients. The FRAX® 10-
year major osteoporotic and hip fracture risks were calculated. Statistical analyses were performed to compare different age groups (60–69 years, 
70–79 years, and ≥80 years). 
Results: The mean 10-year major osteoporotic and hip fracture risks were 13.9% and 78%, respectively. If the National Osteoporosis Foundation 
guidelines were taken into account according to major osteoporotic and hip fracture risks using FRAX® the day before the fracture, treatment 
would not be initiated in 75.8% and 18.9% of patients, respectively. There were significant differences between the age groups according to the 
10-year major osteoporotic and hip fracture probability and fall frequency (p<0.001, p<0.001, and p=0.005, respectively). 
Conclusion: In our study group, the FRAX® 10-year major osteoporotic fracture probability had an underestimation in younger patients with a 
history of frequent falling and did not seem to improve the definition of high-risk patients. The 10-year probability of hip fracture by the FRAX® 
tool can classify populations at risk more effectively. 
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Introduction
Osteoporosis is the most common metabolic disease of 
the bone (1). The measurement of bone mineral density 
with dual energy X-ray absorptiometry (DEXA) is the gold 
standard for the diagnosis of osteoporosis. The World Health 
Organization (WHO) defines a T-score (bone mineral density 
values as compared to young adults) less than -2.5 standard 
deviation (SD) as measured by DEXA as the cutoff value for 
osteoporosis (2). Recent studies revealed that most of the os-
teoporotic fractures occured in individuals with a T-score in 
the osteopenic range, which highlights the clinical risk factors 
for fracture (3,4).
The fracture risk assessment tool (FRAX®) tool was devel-
oped by the WHO collaborating center for metabolic bone dis-
eases to better predict fracture risks based on clinical risk factors. 
The clinical risk factors include age, sex, height, weight, histo-
ry of fragility fracture, parental history of hip fracture, current 
smoking, use of oral glucocorticoids, rheumatoid arhtritis, other 
causes of secondary osteoporosis, and alcohol intake of three or 
more units per day. The FRAX® tool calculates the 10-year prob-
ability of a major osteoporotic (clinical spine, hip, forearm, prox-
imal humerus) fracture (FRAX® major) and hip fracture (FRAX® 
hip) (5). The risk of osteoporotic fracture varies remarkably be-
tween countries. Therefore, the geographic region should be 
considered in fracture risk assesment in addition to clinical risk 
factors. FRAX® models are available for 18 countries, includ-
ing Turkey, where the incidences of both fracture and mortality 
are known (6). The FRAX® model for Turkey was based on hip 
fracture incidence from the Mediterranean Osteoporosis Study 
(MEDOS), which was reported 20 years ago (7). The applica-
tion of FRAX® for the selection of an appropriate group for os-
teoporosis treatment is FRAX® hip >3% or FRAX® major >20% 
according to 2008 National Osteporosis Foundation recommen-
dations (8,9). In Japan, FRAX® major >15% in postmenopausal 
women younger than 75 years and in men have been added to 
the diagnostic criteria and treatment guidelines of osteoporosis 
as reference for determining treatment initiation (10). We aimed 
to calculate the FRAX® values in patients with acute recent hip 
fractures and to investigate the detection rate of patients at a 
high risk according to the Natioanal Osteoporosis Foundation 
guidelines in the Turkish population. 
Material and Methods
Approval of the local ethical committee was obtained prior 
to the study. All of the participants gave written informed con-
sent. Patients who were hospitalized for osteoporotic hip frac-
ture between September 2011 and March 2012 were evaluted 
for the study. A questionnaire including FRAX® variables, demo-
graphic parameters, and fall frequency were recorded. In total, 
80 patients were evaluated during the study period. Patients 
with a pathological femur fracture (n=2), patients older than 90 
years of age (n=5), patients who were not able to complete the 
questionnaire (n=8), and patients with previous osteoporosis 
treatment (n=7) were excluded from the study cohort. Finally, 
the study included 58 patients. Fall frequency was classified into 
four groups and indicated as follows: more frequent than once 
a week, 1; more frequent than once a month, 2; more frequent 
than once a year, 3; and less frequent than once a year, 4. Fall 
frequency was assessed by two questions. First, patients were 
asked “Did you fall during the last one year?” If the answer was 
“No”, the patient was scored 4. If the answer was “Yes”, the 
patient was further asked “Which defines your fall frequency 
best?” Options and scorings were explained as above.
Statistical Analysis
Statistical analysis of the data was performed by the Statisti-
cal Package for Social Sciences (SPSS Inc.; Chicago, IL, USA) 17.0 
for Windows. Descriptive analyses were performed for studied 
parameters. Continuous variables such as FRAX® values were 
expressed as mean±SD of the mean. The Kruskal–Wallis test was 
used to analyse the difference according to age groups which 
were defined as follows: group 1 (n=5), 60–69 years; group 2 
(n=24), 70–79 years; and group 3 (n=29), ≥80 years. Further-
more, the Mann–Whitney U test was used to analyze post-hoc 
comparisons of each group with Bonferroni correction to evalu-
ate the significance found by the Kruskal–Wallis test. Statistical 
significance was defined as a p value of less than 0.05.
Results 
The study included 26 female (44.8%) and 32 male (55.2%) 
patients. The mean age of the study patients was 79.1±6.7 years 
(range, 62–90 years). The mean body mass index (BMI) was 
23.7±3.88 kg/m2 (ranged between 16.6 and 34.2 kg/m2). De-
scriptive parameters of group 1 (n=5, 60–69 years), group 2 
(n=24, 70–79 years), and group 3 (n=26, ≥80 years) are dem-
onstrated in Table 1. 
The most common risk factor was having a previous fracture, 
which was present in 17 (29.3%) patients. Alcohol consumption 
was absent for all of the patients. Table 2 shows the character-
istics of the risk factors of the FRAX® tool in the study group. 
Twenty-one patients (36.2%) had only one FRAX® clinical risk 
factor, 2 patients (3.4%) had more than one clinical risk factor, 
and 35 patients (60.4%) had none of the clinical risk factors. 
The mean FRAX® major and FRAX® hip were 13.9% and 7.8%, 
respectively. If FRAX® major is considered, 44 patients (75.8%) 
were not at a high risk the day before the fracture. Furthermore, 
if FRAX® hip is considered, 11 patients (19%) were not at a high 
risk the day before the fracture. Table 3 represents the distribu-
tion of patients according to FRAX® major <20% and FRAX® hip 
<3%.
When we compared the age groups with Kruskal–Wallis test 
according to different parameters, there was a significant differ-
ence for FRAX® hip, FRAX® major, and fall frequency (p<0.001, 
p<0.001, and p=0.005, respectively). Because of the significant 
difference in FRAX® hip, FRAX® major, and fall frequency param-
eters, the Mann–Whitney U test was used to analyze the post-
hoc comparisons of each group with Bonferroni correction to 
evaluate the significance found by the Kruskal–Wallis test. There 
was a significant difference between groups 1 and 2 accord-
ing to FRAX® hip, FRAX® major, and fall frequency (p<0.001, 
p=0.016, and p=0.004, respectively) and between groups 1 
and 3 (p<0.001, p<0.001, and p=0.005, respectively). On the 
other hand, there was a significant difference between groups 2 
and 3 according to FRAX® hip and FRAX® major (p<0.001 and 
p<0.001, respectively), but there was no significant difference 
according to fall frequency (p=0.881). 
Discussion
Osteoporosis is a highly prevalent metabolic bone disease. 
The development of new evidence-based treatments for osteo-
porosis and the increased importance of the cost effectiveness 
of treatment thresholds have brought about the need for new 
risk prediction models. FRAX® was released in 2008 by WHO to 
provide an assesment tool with use of clinical risk factors (11). 
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In addition to clinical risk factors, the geographic area should 
be considered in fracture risk assessment because fracture prob-
ability varies remarkably among different countries. The FRAX® 
models were based on the epidemiological studies of hip frac-
ture incidence. The FRAX® model for Turkey is based on ME-
DOS. MEDOS is a prospective study, which assessed hip fracture 
rates in 14 centers and 5 countries (7). In 2009, another pro-
spective study was conducted to estimate hip fracture risks in 
Turkey. The FRACTURK study reported that despite still being 
one of the countries with a low fracture risk, the hip fracture 
incidence markedly increased in Turkey. The study proposed the 
recalibration of the FRAX® Turkey model on the basis of new 
fracture incidences (12).
In France, the Os des Femmes de Lyon (OFELY) cohort com-
pared the observed fracture incidence with predicted probabil-
ity from FRAX®. Among women aged at least 65 years with low 
bone mineral density, the 10-year predicted probabilty of major 
osteoporotic fracture with FRAX® was 48% lower than the ob-
served incidence of fracture (13). Therefore, the OFELY cohort 
reported a substantially higher incidence of major osteoporotic 
fractures than the FRAX® predicted probabilty. A similar cohort 
from Spain aimed to compare estimated and observed hip and 
major osteoporotic fracture incidences in women aged at least 
65 years without bone mineral density measurement. The es-
timated risk for hip fractures was similar to the observed frac-
tures; however, the Spanish FRAX® underestimated major os-
teoporotic fractures (14). Kanis et al. (15) proposed the cautious 
interpretation of the results of these external validation studies.
Fraser et al. (16) conducted a study to validate Canadian 
FRAX® in a large Canadian population-based study (CAMOS). 
They concluded that the Canadian FRAX® tool provides predic-
tions consistent with observed fracture rates in the Canadian 
population. Despite Spanish and French external validation 
studies, the CAMOS study reported that the Canadian FRAX® 
tool showed good calibration and discrimination for both major 
osteoporotic and hip fractures. 
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Table 1. Descriptive parameters of the study population according to age groups
Parameter  n Mean±SD 95% CI Min–max
FRAX® Hip 60–69 years 5 0.9±0.5 0.243–1.716 0.4–1.8
 70–79 years 24 4.7±2.8 3.577–6.014 1.2–11.0
 ≥80 years 29 11.6±5.4 9.531–13.669 3.5–24.0
 Total 58 7.8±5.7 6.355–9.382 0.4–24.0
FRAX® Major 60–69 years 5 4.3±1.9 1.924–6.795 2.3–7.2
 70–79 years 24 9.7±5.2 7.541–11.974 3.6–22.0
 ≥80 years 29 19.1±8.9 15.747–22.590 6.4–36.0
 Total 58 13.9±8.9 11.639–16.356 2.3–36.0
Fall frequency 60–69 years 5 2.2±0.4 1.644–2.755 2.0–3.0
 70–79 years 24 3.5±0.8 3.126–3.873 1.0–4.0
 ≥80 years 29 3.4±0.8 3.167–3.798 1.0–4.0
 Total 58 3.3±0.8 3.144–3.614 1.0–4.0
BMI 60–69 years 5 272±5.5 20.396–34.063 21.9–34.2
 70–79 years 24 24.2±3.4 22.837–25.734 16.6–33.3
 ≥80 years 29 22.6±3.3 21.399–23.963 17.5–31.1
 Total 58 23.7±3.7 22.745–24.729 16.6–34.2
BMI: body mass index; Min: minimum; Max: maximum; N: number of patients; SD: standard deviation; FRAX«: fracture risk assessment tool
Table 2. Baseline characteristics of the risk factors of the FRAX® 
tool in the study group 
FRAX® Risk factor (n) Mean or percentage
Age, years (58) 79.1 (range, 60–90)
Body mass index, kg/m2 (58) 23.7 (range, 16.6–34.2)
Previous fracture (17) 29.3%
Parent hip fracture (2) 3.4%
Current smoking (5) 8.6%
Current glucocorticoid use (2) 3.4%
Alcohol consumption (0) 0%
Rheumatoid arthritis (1) 1.7%
Secondary osteoporosis (4) 6.9%
n: number of patients; FRAX«: fracture risk assessment tool
Table 3. Patient distribution according to FRAX® major <20% and 
FRAX® hip <3%
Age (n) FRAX® major <20% FRAX® hip <3%
60–69 years (5) 5 (100%) 5 (100%)
70–79 years (24) 23 (95.8%) 6 (25%)
≥80 years (29) 16 (55.1%) 0
Total (58) 44 (75.8%) 11 (18.9%)
n: number of patients; FRAX«: fracture risk assessment tool
In Turkey, there are no external validation or calibration stud-
ies regarding FRAX® yet. In this study, we obtained the FRAX® 
10-year fracture probability in a population who recently had 
osteoporotic hip fractures. We aimed to document whether os-
teoporosis treatment would be initiated according to the FRAX® 
probabilities and National Osteoporosis Foundation guidelines 
the day before the fracture. If the 10-year probability of osteo-
porotic fracture is considered, 75.8% of patients were not at 
a high risk and osteoporosis treatment would not be initiated. 
However, if the 10-year probability of osteoporotic hip fracture 
is considered, 19% of patients were not at a high risk and would 
be followed without treatment. In our study group, the FRAX® 
10-year major osteoporotic fracture probability does not seem 
to improve the definition of high-risk patients. The increase of 
hip fracture incidence in Turkey in the last 20 years, as docu-
mented by the FRACTURK study, may explain this underestima-
tion. The FRAX® Turkey model may be recalibrated in the light 
of recent prospective studies regarding fracture incidence. If a 
calibration is not performed, the 10-year probabilty of hip frac-
ture seems to define populations at risk more effectively.
We performed further analysis of FRAX® major and FRAX® 
hip according to age groups and determined statistically sig-
nificant differences between group 1, group 2, and group 3. 
FRAX® major and FRAX® hip were lower between individuals 
aged 60 and 69 years than older ages. However, fall frequency 
was significantly higher in group 1 than in group 2 and group 
3. According to our results, it can be assumed that younger 
patients, although having lower FRAX® major and FRAX® hip, 
experience hip fractures if they fall frequently. In group 1, none 
of the patients were at a high risk, according to the National 
Osteoporosis Foundation guidelines. FRAX® could not evaluate 
fall frequency, and our results show a possible underestimation 
of fracture risk between 60 and 69 years of age if there is a his-
tory of frequent falls. Fall frequency was not evaluated in previ-
ous similar studies with FRAX® and external validation studies of 
FRAX® (13,16,17). 
FRAX® aims to improve risk assesment by evaluating clini-
cal risk factors. In our study group, 60.4% of patients had no 
clinical risk factors. This may also contribute to the possible 
underestimation of the FRAX® Turkey model. The mean age 
of our study population (79.1 years) was relatively high com-
pared with a similar study (17). Independent of clinical risk 
factors, increasing age may be simply used for treatment ini-
tiation. A similar study was conducted in Switzerland in pa-
tients who recently had osteoporotic fracture. The treatment 
thresholds for the FRAX® 10-year fracture probabilities were 
proposed according to age groups in this study. It was reported 
that the proposed thresholds were not able to classify patients 
at a high risk in 50%–70% of the studied population (17). Our 
study had several limitations. The study population was small, 
thereby limiting our results. There is a need for further studies 
in large Turkish patient populations. The study comprised pa-
tients with osteoporotic hip fractures. However, patients who 
had osteoporosis without a hip fracture or patients with dif-
ferent fracture sites were not considered as a control group, 
thereby limiting our results in the border of hip fracture. Fur-
ther studies that include the other sites of fractures in the Turk-
ish population are needed.
The aim of this study was not to perform external valida-
tion. Debates on the methodology of external validation stud-
ies regarding the FRAX® tool are ongoing (15,18). We assesed 
whether FRAX® could detect patients at a high risk the day be-
fore the fracture. FRAX® hip could detect vast majority of pa-
tients at a high risk. FRAX® major should be used with caution 
if the treatment goal is the prevention of hip fracture more than 
fractures at other sites. There is a possible underestimation with 
the use of FRAX® major, particularly in younger patients with a 
history of frequent falling. The study group consisted of patients 
with hip fractures. This may explain the better definition of high 
risk with the 10-year probability of hip fracture obtained with 
FRAX®. 
Conclusion
We documented that the FRAX® 10-year major osteoporotic 
fracture probability had an underestimation in younger patients 
with a history of frequent falling and did not seem to improve 
the definition of high-risk patients. The 10-year probability of 
hip fracture of the current FRAX® tool can classify populations 
at risk more effectively.
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